



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/026,949
Filing Date	December 27, 2001
First Named Inventor	Yusuf K. HAMIED et al.
Group Art Unit	1624
Examiner Name	Unassigned <i>Coleman</i>

Attorney Docket Number

33396-177202

RECEIVED

OCT 09 2003

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
BC	A1	6,251,895		Larsen et al.	06-26-2001
	A2				
	A3				
	A4				
	A5				

TC 1700

class 514 subclass 220

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
BC	B1	EP	0831097		Lilly and Co.	03-25-1998
BC	B2	EP	0733635		Lilly and Co.	09-25-1996
BC	B3	WO	0018408		Lilly and Co.	04-06-2000
	B4					
	B5					

T₆

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
* BC	C1	Houben-WEYL, "Methoden der organischen Chemie, Band I/1, Allgemeine Laboratoriumspraxis I" 1958, GEORG THIEME VERLAG, STUTTGART XP002163768, pp. 381-382				
	C2					
	C3					
	C4					
	C5					

** Structures only*

Examiner Signature	Brenda Coleman	Date Considered	Nov. 18, 2003

RECEIVED
OCT 10 2003
TECH CENTER 1600/2900

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DC29489903

VENABLE
ATTORNEYS AT LAW

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			Atty Docket: 33396-177202		Application No.: Unknown 10/026,949		
			Applicant: Y. HAMIED et al				
			Filing Date: December 27, 2001		Group: 1624		
U.S. PATENT DOCUMENTS							
Examiner Initial		U.S. Patent No.	Date	Name	Class	Sub-Class	Filing Date
	AA						
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
BC	AB ✓	R. Narendran et al. "Olanzapine Therapy in Treatment-Resistant Psychotic Mood Disorders: A Long-Term Follow-Up Study", <u>J Clin Psychiatry</u> . 62:7, July 2001, pp. 509-516.					
BC	AC ✓	J. Kando et al. "Olanzapine: A new Antipsychotic Agent with Efficacy in the Management of Schizophrenia", <u>The Annals of Pharmacotherapy</u> . November, 1997, Vol. 31, pp. 1325-1334.					
BC	AD ✓	P. Tran et al. "Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders", <u>Journal of Clinical Psychopharmacology</u> . Vol. 17, No. 5, pp. 407-418, 1997					
BC	AE ✓	F. Bymaster et al. "In Vitro and In Vivo Biochemistry of Olanzapine: A Novel, Atypical Antipsychotic Drug", <u>J Clin Psychiatry</u> . 1997; 58 (suppl 10), pp. 28-36.					
BC	AF ✓	C. Beasley et al. "Efficacy of Olanzapine: An Overview of Pivotal Clinical Trials", <u>J Clin Psychiatry</u> . 1997; 58 (suppl 10), pp. 7-12.					
BC	AG ✓	W. Glazer. "Olanzapine and the New Generation of Antipsychotic Agents: Patterns of Use", <u>J Clin Psychiatry</u> . 1997; 58 (suppl 10), pp. 18-21.					
BC	AH ✓	The Medical Letter, "On Drugs and Therapeutics". January 17, 1997, Vol. 38 (Issue 992), pp. 5-6.					
BC	AI ✓	C. Nemeroff. "Dosing the Antipsychotic Medication Olanzapine", <u>J Clin Psychiatry</u> . 1997; 58 (suppl 10), pp. 45-49.					
BC	AJ ✓	C. Guille et al. "A Naturalistic Comparison of Clozapine, Risperidone, and Olanzapine in the Treatment of Bipolar Disorder", <u>J Clin Psychiatry</u> . 61:9, September 2000, pp. 638-642.					
BC	AK ✓	W. Clark et al. "The Effects of Olanzapine in Reducing the Emergence of Psychosis Among Nursing Home Patients with Alzheimer's Disease", <u>J Clin Psychiatry</u> . 62:1, January 2001, pp. 34-39.					
BC	AL ✓	K. Littrell et al. "Switching Clozapine Responders to Olanzapine", <u>J Clin Psychiatry</u> . 61:12, December 2000, pp. 912-915.					
BC	AM ✓	J. Gomez et al. "Superior Efficacy of Olanzapine Over Haloperidol: Analysis of Patients with Schizophrenia From a Multicenter international Trial", <u>J Clin Psychiatry</u> . 2001:62, (suppl 2), pp. 6-10.					
BC	AN	M. Tohen et al. "Olanzapine Versus Placebo in the Treatment of Acute Mania", <u>Am J Psychiatry</u> . 156:5, May 1999, pp. 702-709.					
Examiner <u>Brenda Coleman</u>				Date Considered <u>Nov. 18, 2003</u>			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							



Application No.
10/026,949
89/540,749

FORM PTO-1449		Atty Docket 33396-153020
INFORMATION DISCLOSURE STATEMENT		Filing Date March 31, 2000
		Group 1624 Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
BC	BA	4,115,574	9/19/78	Chakrabarti et al.	424	250	
BC	BB	5,457,101	10/10/95	Greenwood et al.	514	220	
BC	BC	5,627,178	5/6/97	Chakrabarti et al.	514	220	
BC	BD	5,631,250	5/20/97	Bunnell et al.	514	220	
BC	BE	5,637,584	6/10/97	Larsen	514	220	
BC	BF	5,703,232	12/30/97	Bunnell et al.	540	557	
BC	BG	5,817,655	10/6/98	Chakrabarti et al.	514	220	
BC	BH	5,817,656	10/6/98	Beasley, Jr. et al.	514	220	
BC	BI	5,817,657	10/6/98	Beasley, Jr. et al.	514	220	

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

BC	BJ	Drugs of the Future, Olanzapine, 1994, Vol. 19(2), pp. 114-117.
BC	BK	Chakrabarti et al., 4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as Potential Neuroleptics, J. Med. Chem, 1980, Vol. 23, pp. 878-884.

Examiner Branda Colamed Date Considered Mar 27, 2004

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

#4

Page 5 of 5

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			Atty Docket 33396-15302	Application No. 10/036,949 09/548,749				
			Filing Date March 31, 2000			Group 1624 Not Yet Assigned		
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date	
BC	AA	5,919,485	7/6/99	Cochran et al.	424	480	10/036,949	
BC	AB	5,736,541	4/7/98	Bunnell et al.	514	220	12/27/01	
BC	AC	5,229,382	7/20/93	Chakrabarti et al.	514	220	10/036,949	
BC	AD	5,605,897	2/25/97	Beasley, Jr. et al.	514	220	12/27/01	
BC	AE	4,115,568	9/19/78	Chakrabarti et al.	424	250		
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Sub-Class	Trans-lation	
	AF							
	AG							
	AH							
	AI							
	AJ							
	AK							
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)								
BC	AL	Chakrabarti, et al., 10-Piperazinyl-4H-thieno[3.2-b][1-5]- and -[3.4-b][1,5]benzodiazepines as Potential Neuroleptics, J. Med. Chem. 1980, Vol. 23, 884-889.						
BC	AM	Chakrabarti, et al., Effects of Conformationally Restricted 4-Piperazinyl-10H-thienobenzodiazepine Neuroleptics on Central Dopaminergic and Cholinergic Systems, J. Med. Chem., 1982, Vol. 25, pp. 1133-1140.						
Xaminer	<i>Brenda Coleman</i>					Date Considered Nov. 18, 2003 <i>March 27, 2004</i>		
XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.								